吉利德科学的争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
2022
340B合同药房限制争议
艾滋病医疗基金会公开指控吉利德通过340B合同药房非法限制某些药物的获取，并在倡导广告中使用“Greediad”一词。所提供来源记录了该组织的指控和活动，而非最终法律裁决。
2019
美国政府就 PrEP 专利权起诉吉利德科学
提起诉讼
在一起涉及吉利德科学的法律纠纷中，美国卫生与公众服务部就 Truvada 和 Descovy 用于 HIV 预防的专利权提起诉讼。诉状称政府拥有相关 PrEP 专利。这些是诉讼中的主张，并非法院裁定。该事件涉及 HIV 预防药物的专利争议以及所主张的 PrEP 相关专利所有权。
美国卫生与公众服务部就 Truvada 和 Descovy 用于 HIV 预防的专利权起诉 Gilead Sciences。诉状称政府拥有相关 PrEP 专利；这是诉讼主张，并非法院裁定。
品牌回应
否认 — Gilead
In response, Gilead said the government’s patent claims were “invalid.”
来源摘录
The lawsuit, filed Wednesday in U.S. District Court for the District of Delware, alleges that CDC researchers began studying the preventive use of HIV treatment drugs — like tenofovir, or TDF, and emtricitabine, FTC, the two compounds in a Truvada tablet — as early as 1998, before Gilead sought a patent.
Crucially, the lawsuit alleges that the government owns the PrEP patent for both Truvada and Descovy, Gilead’s next generation PrEP approved last month, setting up the possibility that both HIV prevention drugs could see drastic price reductions.
In response, Gilead said the government’s patent claims were “invalid.”